Valsartan Dosing in Hypertension with Renal Impairment
For hypertension, start valsartan at 80-160 mg once daily and titrate up to a maximum of 320 mg once daily as needed; no dose adjustment is required for renal impairment unless creatinine clearance is below 10 mL/min, but close monitoring of renal function, blood pressure, and electrolytes is essential. 1
Standard Dosing for Hypertension
Initial dose: 80-160 mg once daily for patients who are not volume-depleted, with the higher starting dose (160 mg) reserved for those requiring greater blood pressure reductions 1
Maximum dose: 320 mg once daily for hypertension, though antihypertensive effect increases substantially within 2 weeks and reaches maximum reduction after 4 weeks 1
The dose-response relationship is predictable across the 20-320 mg range, with the 160 mg dose providing enhanced efficacy compared to 80 mg while maintaining a tolerability profile comparable to placebo 2
Adding a diuretic has greater antihypertensive effect than dose increases beyond 80 mg, making combination therapy with hydrochlorothiazide a preferred strategy for inadequate blood pressure control 1
Target Blood Pressure Goals
Target BP <130/80 mm Hg for most patients with hypertension, or <140/80 mm Hg in elderly patients 3
For patients with chronic kidney disease (CKD), the same BP target of <130/80 mm Hg applies, with RAS inhibitors like valsartan being first-line agents because they reduce albuminuria in addition to controlling blood pressure 3
Renal Impairment Considerations
No specific dose adjustment is required in the FDA labeling for patients with renal impairment, though the dose should not exceed 80 mg once daily in patients with hepatic dysfunction 4
Valsartan can be used in patients with creatinine clearance >10 mL/min without dose adjustment 4
Exercise caution when creatinine >221 μmol/L (>2.5 mg/dL) or eGFR <30 mL/min/1.73 m², with specialist consultation recommended 5
An increase in creatinine up to 50% above baseline or to 3 mg/dL is acceptable, but if creatinine rises by 100% or exceeds 4 mg/dL, seek specialist advice 5
Essential Monitoring Protocol
Monitor renal function, electrolytes, and blood pressure within 1-2 weeks after initiation or dose increases, then every 3-6 months during maintenance therapy 5, 6
Monitor for hyperkalemia (K+ >5.0 mmol/L), which requires caution and specialist advice; avoid potassium supplements, potassium-sparing diuretics, and "low-salt" substitutes with high potassium content 5
Avoid NSAIDs unless essential, as they may attenuate diuretic effects, worsen renal function, and interfere with blood pressure control 5, 6
Loop diuretics should be used instead of thiazides if eGFR <30 mL/min/1.73 m² 3
Critical Safety Warnings
Never combine valsartan with ACE inhibitors routinely, as this increases the risk of hyperkalemia and renal dysfunction without additional mortality benefit 5, 6
Avoid the triple combination of ARB + ACE inhibitor + mineralocorticoid receptor antagonist, which significantly increases adverse renal and electrolyte complications 7, 5
For symptomatic hypotension, reconsider the need for nitrates, calcium-channel blockers, and other vasodilators; reduce or stop if possible 5
Asymptomatic hypotension does not require treatment changes 5